Phaseline

Companies › Sinocelltech

Sinocelltech: clinical trials, targets and expected readouts

10 active drug programs in 16 registered trials: 7 Phase 3, 6 Phase 1, 2 Phase 2, 1 Phase 4; Oncology, Infectious disease, Immunology, Hematology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SCTC21C
anti-CD38 monoclonal antibody
CD38Phase 3Multiple Myeloma (MM); Amyloidosis; Relapsed or Refractory Hematologic MalignanciesFeb 2027
SCTB35
Unclear - investigational compound
–Phase 3DLBCL - Diffuse Large B Cell Lymphoma; Follicular Lymphoma (FL); System Lupus ErythematosusMay 2027
SCTB14–Phase 3Non-Small Cell Lung Carcinoma (NSCLC)Jul 2027
Recombinant 14-Valent Human Papillomavirus Vaccine (Insect Cell)
14-valent HPV vaccine
–Phase 3HPV InfectioNAug 2028
Omfiloctocog Alfa (SCT800)
Coagulation factor VIII exogenous protein
F8Phase 3Haemophilia A; Hemophilia A With InhibitorDec 2028
SCT650C
Anti-IL-17A antibody
IL17APhase 2Hidradenitis Suppurativa (HS)Mar 2027
SCTB41–Phase 2Double Blind; Advanced Malignant Solid TumoursApr 2027
SCT520FF–Phase 1nAMDJan 2027
SCTV02
Recombinant respiratory syncytial virus (RSV) vaccine
–Phase 1Respiratory Syncytial VirusJul 2027
SCTB39-1–Phase 1Advanced Malignant Solid TumorJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05888870Omfiloctocog Alfa (SCT800)Phase 4Hemophilia A With InhibitorHematologyDec 2026
NCT06672536SCT520FFPhase 1nAMDOphthalmologyJan 2027
NCT06252298SCTC21CPhase 1Relapsed or Refractory Hematologic MalignanciesOncologyFeb 2027
NCT07244510SCT650CPhase 2Hidradenitis Suppurativa (HS)ImmunologyMar 2027
NCT06600022SCTB41Phase 1Advanced Malignant Solid TumoursOncologyApr 2027
NCT06841042SCTB35Phase 1System Lupus ErythematosusImmunologyMay 2027
NCT07362459SCTB14Phase 3Non-Small Cell Lung Carcinoma (NSCLC)OncologyJul 2027
NCT06754605SCTV02Phase 1Respiratory Syncytial VirusInfectious diseaseJul 2027
NCT07570823SCTB35Phase 3DLBCL - Diffuse Large B Cell LymphomaOncologyNov 2027
NCT07297329SCTC21CPhase 3Multiple Myeloma (MM)OncologyDec 2027
NCT07388602SCTC21CPhase 3AmyloidosisMetabolic and endocrineDec 2027
NCT07562022SCTB35Phase 3Follicular Lymphoma (FL)OncologyMay 2028
NCT07050641SCTB39-1Phase 1Advanced Malignant Solid TumorOncologyJun 2028
NCT06041061Recombinant 14-Valent Human Papillomavirus Vaccine (Insect Cell)Phase 3HPV InfectioNInfectious diseaseAug 2028
NCT07437404Omfiloctocog Alfa (SCT800)Phase 3Haemophilia AHematologyDec 2028
NCT07662395SCTB41Phase 2Double BlindOncologyJan 2030

Targets

F8 (1) CD38 (1) IL17A (1)

Companies with the same targets

Celltrion Pfizer Roche Biocad Swedish Orphan Biovitrum Octapharma ASC Therapeutics Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics

Companies built like this

Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Innovent Biopharmaceutical Technology (Hangzhou) Chipscreen Biosciences Telix Pharmaceuticals (Innovations)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.